INSPIRE Initiative Launched by BD to Elevate IV Line Safety and Nursing Excellence Across India
Participants at BD India and INS Indias Nursing Summit INSPIRE
The first INSPIRE event, organized in Pune, brought together over 50 nursing leaders and educators from top hospitals across the city. The event focused on advancing infusion therapy standards, promoting a culture of safety, and fostering collaboration among nursing professionals.
Col. Binu Sharma, President of INS India, commending BD India for creating a platform that convenes senior nursing heads said, 'Initiatives like INSPIRE are vital for nurturing a safe Infusion therapy culture and empowering upcoming nurses. With a goal to reach over 5,000 nurses across major metros, the INSPIRE program will continue through city-based events and in-hospital training, culminating in a national recognition ceremony at the INS Conference in November 2025.'
Atul Grover, Managing Director, BD India/South Asia, said, 'The INSPIRE initiative is an effort to transform IV-line care practices through learning and collaboration amongst nursing professionals. Our continued collaboration with INS over the years and now for INSPIRE, underscores the shared commitment to improving clinical standards, fostering professional development, and ensuring the highest levels of patient safety. This is aligned with our purpose of working with like-minded partners to advance the world of health.'
The Pune CME featured sessions on needle stick injury prevention, infusion safety, and CRBSI guidelines, followed by a panel discussion titled 'Safeguarding Care: A Dual Focus on Patient and Healthcare Worker Safety.' Experts from leading healthcare institutions shared real-world insights and strategies to improve safety outcomes.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
06-08-2025
- Fashion Value Chain
INSPIRE Initiative Launched by BD to Elevate IV Line Safety and Nursing Excellence Across India
To elevate IV-line safety and enable nursing excellence, BD (Becton, Dickinson and Company), in collaboration with the Infusion Nurses Society (INS) India, has launched the INSPIRE program- Infusion Nursing Summit for Practice, Innovation, Recognition & Excellence across all INS state and city chapters in India. Participants at BD India and INS Indias Nursing Summit INSPIRE The first INSPIRE event, organized in Pune, brought together over 50 nursing leaders and educators from top hospitals across the city. The event focused on advancing infusion therapy standards, promoting a culture of safety, and fostering collaboration among nursing professionals. Col. Binu Sharma, President of INS India, commending BD India for creating a platform that convenes senior nursing heads said, 'Initiatives like INSPIRE are vital for nurturing a safe Infusion therapy culture and empowering upcoming nurses. With a goal to reach over 5,000 nurses across major metros, the INSPIRE program will continue through city-based events and in-hospital training, culminating in a national recognition ceremony at the INS Conference in November 2025.' Atul Grover, Managing Director, BD India/South Asia, said, 'The INSPIRE initiative is an effort to transform IV-line care practices through learning and collaboration amongst nursing professionals. Our continued collaboration with INS over the years and now for INSPIRE, underscores the shared commitment to improving clinical standards, fostering professional development, and ensuring the highest levels of patient safety. This is aligned with our purpose of working with like-minded partners to advance the world of health.' The Pune CME featured sessions on needle stick injury prevention, infusion safety, and CRBSI guidelines, followed by a panel discussion titled 'Safeguarding Care: A Dual Focus on Patient and Healthcare Worker Safety.' Experts from leading healthcare institutions shared real-world insights and strategies to improve safety outcomes. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.
The Hindu
22-07-2025
- The Hindu
KLE Society hospital of Belagavi first to go paperless in State
In a record of sorts, KLE Society's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi, has earned the credit of being the first fully paperless hospital in the State. Addressing presspersons in Belagavi on Tuesday, Medical Director of the hospital M. Dayananda termed it a significant step towards digital transformation in healthcare. The hospital has achieved the milestone under the leadership of Chairman of KLE Society Prabhakar Kore and director Amit Kore and others. Dr. Dayananda said: 'This digital transformation is a reflection of our continuous pursuit of excellence in patient care. By going paperless in a 1,200-bed healthcare set-up, we have significantly reduced hospital turnaround time, enabling faster decision-making and a smoother patient care journey.' Elaborating on the initiative, he said that all clinical, administrative and operational processes in the hospital have been fully digitized with the help of Presco, a unique health-tech innovation award-winning technology. Dr. Dayananda said that the new digital platform is fully compliant with the Ayushman Bharat Digital Mission (ABDM) guidelines, ensuring seamless integration with India's national digital health ecosystem and offering the highest standards of data privacy and cyber security. And, the digital shift has been made possible through dedicated collaboration between hospital leadership, IT team and the Presco team, he said. He said that the KLE Society has plans to extend the paperless transformation to all its hospitals in the country. KLE Hospital in Belagavi handles over 50,000 patient records annually and the digital transformation is estimated to save over 10 million to 12.5 million pages each year.
&w=3840&q=100)
Business Standard
21-07-2025
- Business Standard
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
Sun Pharmaceutical Industries has announced that its psoriasis drug ILUMYA (tildrakizumab 100 mg) delivered positive results in two late-stage clinical trials for active psoriatic arthritis (PsA), potentially paving the way for regulatory filings in the United States. The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24. INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose. Consistent safety profile supports regulatory case Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified. ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities. Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals. Targeting IL-23 in chronic inflammatory pathways ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk. Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed. Strategic pipeline strengthens global presence Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
